Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors

被引：0
|
作者：
Li Pomi, Federica [1 ]
Vaccaro, Federico [2 ]
Borgia, Francesco [1 ]
Irrera, Natasha [1 ]
Vaccaro, Mario [1 ]
机构：
[1] Univ Messina, Dept Clin & Expt Med, Sect Dermatol, I-98125 Messina, Italy
[2] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy
来源：
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 159卷 / 02期
关键词：
D O I：
10.23736/S2784-8671.23.07781-2
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：212 / 214
页数：3
相关论文
共 50 条
  • [21] Lazertinib: breaking the mold of third-generation EGFR inhibitors
    Patel, Kishan B.
    Heppner, David E.
    RSC MEDICINAL CHEMISTRY, 2025, 16 (03): : 1049 - 1066
  • [22] Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
    Yu, Danlei
    Zhao, Wen
    Vallega, Karin A.
    Sun, Shi-Yong
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 1 - 10
  • [23] Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
    Jabbour, Elias
    Kantarjian, Hagop
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (06): : 323 - 334
  • [24] Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?
    Wang, Fen
    Adjei, Alex A.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (06) : 881 - 883
  • [25] Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
    R. Califano
    N. Tariq
    S. Compton
    D. A. Fitzgerald
    C. A. Harwood
    R. Lal
    J. Lester
    J. McPhelim
    C. Mulatero
    S. Subramanian
    A. Thomas
    N. Thatcher
    M. Nicolson
    Drugs, 2015, 75 : 1335 - 1348
  • [26] Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
    Califano, R.
    Tariq, N.
    Compton, S.
    Fitzgerald, D. A.
    Harwood, C. A.
    Lal, R.
    Lester, J.
    McPhelim, J.
    Mulatero, C.
    Subramanian, S.
    Thomas, A.
    Thatcher, N.
    Nicolson, M.
    DRUGS, 2015, 75 (12) : 1335 - 1348
  • [27] Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands
    Niggenaber, Janina
    Heyden, Leonie
    Grabe, Tobias
    Mueller, Matthias P.
    Lategahn, Jonas
    Rauh, Daniel
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (12): : 2484 - 2490
  • [28] AURORA KINASE A IS RESPONSIBLE OF RESISTANCE TO THIRD-GENERATION ANTI-EGFR INHIBITORS IN LUNG CANCER
    不详
    ESMO OPEN, 2019, 4 (01)
  • [29] A Retrospective Study of Non-Small Cell Lung Cancer Treated with Second- and Third-Generation EGFR Tyrosine Kinase Inhibitors
    Mitsuya, S.
    Tsuruoka, K.
    Kanaoka, K.
    Funamoto, T.
    Tsuji, H.
    Matsunaga, N.
    Nakamura, T.
    Tamura, Y.
    Imanishi, M.
    Ikeda, S.
    Fujisaka, Y.
    Goto, I.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S596 - S596
  • [30] Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC
    Park, Ha-Ram
    Kim, Tae Min
    Lee, Yusoo
    Kim, Soyeon
    Park, Seongyeol
    Ju, Young Seok
    Kim, Miso
    Keam, Bhumsuk
    Jeon, Yoon Kyung
    Kim, Dong-Wan
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (11) : 1859 - 1871
12345